Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Laboratorio de Genetica e Diagnostico Molecular, |
RCV002252005 | SCV002523053 | uncertain significance | See cases | 2022-03-08 | criteria provided, single submitter | clinical testing | ACMG classification criteria: PM2, PP3 |
Labcorp Genetics |
RCV002514863 | SCV003271424 | uncertain significance | Intellectual disability | 2022-06-14 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Benign"; Align-GVGD: "Class C15"). ClinVar contains an entry for this variant (Variation ID: 161752). This variant has not been reported in the literature in individuals affected with GABRB2-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces arginine, which is basic and polar, with cysteine, which is neutral and slightly polar, at codon 193 of the GABRB2 protein (p.Arg193Cys). |
Science for Life laboratory, |
RCV000149288 | SCV000088930 | unknown | Malignant tumor of prostate | no assertion criteria provided | not provided | Converted during submission to Uncertain significance. |